ZFP36 and prostate carcinoma: Specifically, using a tetracycline-inducible system to activate TTP expression in metastatic PC-3 prostate cancer cells that express low levels of endogenous TTP, we found that TTP blocks proliferation and provokes cell cycle arrest ex vivo and impairs tumorigenicity in vivo.